Inari Medical (NARI) said Tuesday that treatment with FlowTriever showed superiority compared with catheter-directed thrombolytics or CDT in a randomized study that enrolled 550 intermediate-risk pulmonary embolism patients.
The company said the study achieved its primary composite endpoint, with patients experiencing three times fewer clinical deteriorations and/or therapy escalations, and "significantly less" intensive care unit admission and length of stay with FlowTriever compared with CDT.
Inari shares advanced more than 10% in recent trading.
Price: 46.96, Change: +4.40, Percent Change: +10.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。